Sugi Predict

Sugi Predict / Compounds / SCHEMBL7400371

SCHEMBL7400371

SCHEMBL7400371

COCCN1C(C)=C(C(=O)O)C(c2cccc([N+](=O)[O-])c2)(C(C)C)C(C(=O)O)=C1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 4/20 0.43
▸ CYP2C19 P33261 4/20 0.43
▸ CYP2D6 P10635 3/20 0.43
▸ RECQL P46063 1/20 0.43
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ CYP1A2 P05177 3/20 0.41
▸ CYP3A4 P08684 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ THPO P40225 1/20 0.41
▸ IRAK4 Q9NWZ3 1/20 0.41
▸ HTT P42858 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ ADRA1A P35348 4/20 0.38
▸ ADORA3 P0DMS8 4/20 0.38
▸ ADRA2A P08913 3/20 0.38
▸ ADRA2B P18089 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7267495 0.85 CYP2C9 (0.40) CYP2C9CYP2C19CYP2D6RECQLMEN1
SCHEMBL9830227 0.80 HTT (0.47) CYP2C9CYP2C19CYP2D6MEN1KMT2A
SCHEMBL9618019 0.77 CYP2C9 (0.36) CYP2C9CYP2C19CYP2D6RECQLMEN1
SCHEMBL3635766 0.77 CYP2C9 (0.44) CYP2C9CYP2C19CYP2D6RECQLMEN1
SCHEMBL4882577 0.77 CYP2C9 (0.44) CYP2C9CYP2C19CYP2D6RECQLMEN1
SCHEMBL9153403 0.77 CTSA (0.37) MEN1KMT2AMAPTLMNATSHR
SCHEMBL10827655 0.75 F2RL3 (0.36) CYP2C9CYP2C19CYP2D6MEN1KMT2A
SCHEMBL9154812 0.75 NOTUM (0.39) MEN1KMT2AMAPTLMNATSHR
SCHEMBL20801670 0.74 CYP1A2 (0.55) CYP2C9CYP2C19CYP2D6MEN1KMT2A
SCHEMBL4756165 0.74 TP53 (0.43) CYP2C9CYP2C19CYP2D6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260007591-A1 NIMODIPINE COMPOSITION FOR INJECTION BICAZER BIOTECHNOLOGY (GUANGZHOU) CO., LTD (CN) 2026-01-08 — — US disclosed
WO-2019018306-A1 SCALABLE MICROPARTICULATE FORMULATIONS CONTAINING MICRONIZED POLYMORPHIC NIMODIPINE FORM 2 EDGE THERAPEUTICS, INC. (US) 2019-01-24 — — WO disclosed
US-20180098977-A1 SCALABLE MICROPARTICULATE FORMULATIONS CONTAINING POLYMORPHIC NIMODIPINE FORM 2 PREPARED BY A SOLVENT EVAPORATION PROCESS EDGE THERAPEUTICS, INC 2018-04-12 — — US disclosed
US-9914752-B2 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders SYNERGY PHARMACEUTICALS, INC. (US) 2018-03-13 — — US disclosed
WO-2018039039-A1 SCALABLE MICROPARTICULATE FORMULATIONS CONTAINING POLYMORPHIC NIMODIPINE FORM 2 PREPARED BY A SOLVENT EVAPORATION PROCESS EDGE THERAPEUTICS, INC. (US) 2018-03-01 — — WO disclosed
US-20160243188-A1 AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS JPMORGAN CHASE BANK, N.A. 2016-08-25 — — US disclosed
US-9399019-B2 Polymorph compositions, methods of making, and uses thereof EVONIK CORPORATION (US) 2016-07-26 — — US disclosed
US-20140271895-A1 Polymorph Compositions, Methods of Making, and Uses Thereof EDGE THERAPEUTICS, INC. (US) 2014-09-18 — — US disclosed
US-8821944-B1 Polymorph compositions, methods of making, and uses thereof EVONIK CORPORATION 2014-09-02 — — US disclosed
US-20130310328-A1 Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders BAUSCH HEALTH, CANADA INC. (CA) 2013-11-21 — — US disclosed
US-20130302431-A1 Polymorph Compositions, Methods of Making, and Uses Thereof EVONIK CORPORATION 2013-11-14 — — US disclosed
US-20020049155-A1 Cobalamin compounds useful as cardiovascular agents and as imaging agents HOGENKAMP HENRICUS P C (US) 2002-04-25 — — US disclosed
US-5519012-A CALCIUM ANTAGONISTS, CARDIOVASCULAR DISORDERS LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, D.D., LJUBLJANA (SI) 1996-05-21 — — US disclosed
EP-0566142-A1 Inclusion complexes of optically active and racemic 1,4-dihydro pyridines with cyclodextrin derivates LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. (SI) 1993-10-20 — — EP disclosed
EP-0555302-A1 METHOD OF TREATING DEMYELINATING DISEASE THE WELLCOME FOUNDATION LIMITED (GB) 1993-08-18 — — EP disclosed
WO-1992007564-A2 METHOD OF TREATING DEMYELINATING DISEASE THE WELLCOME FOUNDATION LIMITED (GB) 1992-05-14 — — WO disclosed
US-4504476-A Method of administering calcium channel blocking agents SCHWARTZ ARNOLD 1985-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180098977-A1 SCALABLE MICROPARTICULATE FORMULATIONS CONTAINING POLYMORPHIC NIMODIPINE FORM 2 PREPARED BY A SOLVENT EVAPORATION PROCESS CACNA1B, NIM1K, SLC6A4 CYP2C9 550/4885CYP2C19 297/4885CYP2D6 111/4885
US-20020049155-A1 Cobalamin compounds useful as cardiovascular agents and as imaging agents APOB, MMAB, CBS CYP2C9 578/4885CYP2C19 921/4885CYP2D6 1097/4885
US-20140271895-A1 Polymorph Compositions, Methods of Making, and Uses Thereof PGF, BDNF, PYGB CYP2C9 1360/4885CYP2C19 476/4885CYP2D6 915/4885
US-20130302431-A1 Polymorph Compositions, Methods of Making, and Uses Thereof PGF, BDNF, PYGB CYP2C9 1360/4885CYP2C19 476/4885CYP2D6 915/4885
US-20260007591-A1 NIMODIPINE COMPOSITION FOR INJECTION SCN2B, SCN4A, VASP CYP2C9 2262/4885CYP2C19 2445/4885CYP2D6 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.